pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins.

Protein 125

Protein Gene Bioassay DNA 125

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. Under the license agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Protein 52

Protein Licensing Licensing Sales 52

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours.

Development 130

Development Research Antibody Engineer 130

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. OVs can be attenuated natural viruses or recombinant viruses.

Protein 130

Protein Gene Genetics Gene Therapy 130

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. The project is a partnership with Inspirevax and the National Research Council of Canada (NRC).

Vaccination 231

Vaccination Vaccine Development Manufacturing 231

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

Protein 80

Protein Antibody Engineer Development 80

Scienmag

MAY 14, 2021

Approach opens a new avenue to study the biology of acute leukemia and for the development of new drugs Credit: Grembecka / Cierpicki Labs The protein made by the ASH1L gene plays a key role in the development of acute leukemia, along with other diseases.

Protein 70

Protein Development Research Gene 70

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. It enables innovative and collaborative research to rapidly bring new treatment options to patients.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharmaceutical Technology

MARCH 17, 2023

The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

Research 246

Research Antibody Protein Trials 246

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Drug Discovery World

FEBRUARY 14, 2024

Especially for rapidly-mutating viruses (such as SARS-CoV-2), tools that can help inform the rapid development of vaccines are crucial in being better prepared for future health crises. However, such achievements can only be achieved by leveraging research strengths, regulatory capabilities and technical platforms.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

BioPharma Reporter

AUGUST 10, 2023

Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.

Protein 52

Protein Research Drugs Development 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Protein 130

Protein Marketing Manufacturing Reagent 130

Scienmag

NOVEMBER 17, 2021

Researchers have compiled the most comprehensive road map of the protein composition of human lungs, providing a clearer picture of the healthy development of this essential organ that made terrestrial life possible. RICHLAND, Wash.—Researchers

Development 85

Development Research Protein Medicine 85

Medical Xpress

APRIL 19, 2023

Despite its prevalence, and despite many recent advances in the hepatology field, no new treatment interventions for ALD have been developed over the past several decades.

Protein 75

Protein Development Research 75

Drug Discovery World

FEBRUARY 13, 2024

It goes on to show that NX-2127, a potent targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations. The post Protein degrader overcomes resistance in B-cell malignancies appeared first on Drug Discovery World (DDW).

Protein 52

Protein Medicine Scientist Research 52

BioTech 365

JULY 20, 2021

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs In Development, 2021 Research Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Bromodomain Containing Protein 4 (Protein (..)

Protein 40

Protein Containment Development Research 40

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

Medical Xpress

MAY 3, 2023

Cartilage is the tissue that protects bones by providing shock absorption and facilitates smooth joint movement. Due to its limited intrinsic healing capacity, stem cell transplantation is a promising therapeutic approach to address cartilage inflammation and damage, as well as to promote cartilage regeneration.

Protein 98

Protein Development Research 98

Bio Pharma Dive

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Drugs 268

Drugs Protein Scientist Development 268

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

Medical Xpress

APRIL 19, 2023

In research published in The FASEB Journal, scientists have discovered that a molecule called Yes-associated protein (YAP) plays a key role in the development of liver scarring, or fibrosis, by influencing the behavior of premature cells called liver progenitor cells.

Protein 95

Protein Scientist Development Research 95

Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Antibody 59

Antibody Protein Vaccination Vaccine 59

BioPharma Reporter

AUGUST 24, 2023

A research team led by University of California, Irvine scientists has developed an âinnovativeâ method for quickly creating vast collections of chemical compounds used in drug discovery by using ribosomes, the molecules found in all cells that synthesize proteins and peptides.

Development 52

Development Research Protein Scientist 52

Pharmaceutical Technology

DECEMBER 5, 2022

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. The hub will connect Queensland scientists with the teams at Sanofi’s mRNA Centre of Excellence in the US and France, putting them at the front of international vaccine development and biomedical research.

Research 246

Research Gene Therapy Vaccination Vaccine 246

Scienmag

SEPTEMBER 11, 2020

Finding could lead to future treatments for hearing loss Credit: University of Maryland School of Medicine Researchers at the University of Maryland School of Medicine (UMSOM) have conducted a study that has determined the role that a critical protein plays in the development of hair cells. Some of […].

Protein 61

Protein Development Research Medicine 61

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Scienmag

JULY 7, 2022

A collaboration including researchers from Kobe University, University of Tokyo and Tohoku University has successfully identified and disrupted genes in the yeast Pichia pastoris (1) in order to increase its secretory production of useful proteins (2).

Protein 88

Protein Production Gene Development 88

XTalks

APRIL 26, 2022

California-based startup Air Protein developed an alt meat called Air Meat, which is made using microbes that turn recycled carbon dioxide (CO2) into protein. So, how does the company make alt protein out of thin air? So, how does the company make alt protein out of thin air?

Protein 97

Protein Branding Production Scientist 97

Scienmag

NOVEMBER 11, 2020

Credit: Masato Kanemaki Researchers can now more accurately and precisely target specific proteins in yeast, mammalian cells and mice to study how knocking down specific protein traits can influence physical manifestation in a cell or organism. “Conditional gene knockout and small interfering RNA […].

Protein 98

Protein Genetics RNA Development 98

Drug Discovery World

NOVEMBER 29, 2022

Using artificial intelligence, researchers at Chalmers University of Technology, Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. . The technology can contribute to the development and production of vaccines and drugs for severe diseases much faster and at lower cost. .

DNA 52

DNA Development Research Drugs 52

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection. Human-first precision health.

Development 134

Development Research Drugs Clinical Trials 134

Drug Discovery World

MAY 4, 2023

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials.

Engineer 52

Engineer Protein Life Science Medicine 52

Drug Discovery World

NOVEMBER 7, 2023

As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated.

Protein 52

Protein Development Drugs Research 52

BioTech 365

AUGUST 11, 2021

Middle East Respiratory Syndrome Coronavirus Spike Protein Drugs Development Market Research Report 2021 – ResearchAndMarkets.com Middle East Respiratory Syndrome Coronavirus Spike Protein Drugs Development Market Research Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Middle East Respiratory Syndrome (..)

Protein 40

Protein Marketing Development Research 40